ArticleAnnals of surgical oncology2025
Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Advancing surgical outcomes for retroperitoneal tumors.Frontiers in surgery · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerivascular epithelioid cell tumors (PEComa) are a rare family of mesenchymal tumors that include several subtypes. There are very limited data describing the natural history of patients with extra-visceral retroperitoneal PEComas of the retroperitoneum. The aim of this study is to describe the clinical features, treatment patterns, outcomes, and diagnostic challenges of primary extra-visceral retroperitoneal or abdominopelvic PEComa over the past decade. PATIENTS AND
methodsThis is a retrospective analysis of all extra-visceral, non-renal, retroperitoneal, or abdominopelvic PEComas treated at participating centers over the past 10 years.
resultsA total of 77 patients from 13 centers were included. The median age at diagnosis was 56 years (range 18-81 years); 73% were female. The median size was 9 cm. The tumor was classified as a PEComa not otherwise specified (NOS) in 55 (71%), sclerosing PEComa in 11 (15%), and angiomyolipoma (AML) in 11 (15%). Treatment intent was curative in 59 (77%) patients. Adjuvant radiation was given in five (8%) patients, and (neo)adjuvant systemic therapy was given to six (10%). Of those who did not undergo curative intent treatment, four (22%) patients had metastatic disease and three (17%) had primary unresectable disease. With a median follow-up of 26 months (2.3-147 months), 24 (40%) of the 59 patients having curative treatment had recurred. Recurrence rates differed by subtype, with 20 (37%) of the PEComa NOS group, 3 (27%) of the sclerosing PEComa group, and 1 (9%) of the AML group developing recurrence. The estimated 5-year OS of the whole cohort was 63% and 75% for the curative intent group.
conclusionsRetroperitoneal and abdominopelvic PEComas show distinct behaviors by subtype. PEComa NOS had the highest recurrence and mortality, sclerosing PEComa showed intermediate risk, and AML was indolent. Histological classification is essential for prognosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.